Service resources: Oncology
# The Novartis Breast Cancer Health Inequalities Tool

The Novartis Breast Cancer Health Inequalities (BC HI) Tool brings together a range of datasets to build a greater understanding of the drivers behind the current variation that exists across breast cancer pathways, as well as in breast cancer patient outcomes, at a national and local level across England.

The BC HI interactive dashboard-based tool can highlight relationships between breast cancer and socioeconomic factors, such as deprivation, ethnicity and rurality, at different stages of disease and within different age groups.

The BC HI Tool showcases a variety of real-world data, such as cancer referrals, stage of diagnosis, survival and quality of life metrics, as well as an in-depth analysis of Hospital Episode Statistics data to highlight disparity, variation and unmet need, both nationally and at a system level (Cancer Alliance/ICS).

Image

System inequalities

Image

Quality of Life in Breast Cancer Patients by Integrated Care Board

Click for more information

Wilmington Healthcare

| Home | Cancer Wait Times | Cancer Stage | Cancer Survival | Quality of Life | Patient Inequalities | System Inequalities | Methodology | Disclaimer |

Organisation Type
Integrated Care Board

Organisation Name
(All)

Metric
% who reported any lev...

Reported problem
Anxiety / depression

Category
Age group

This work uses data that has been provided by patients and collected by the NHS as part of their care and support. The data is collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of NHS England (NHSE) and licensed under the Open Government Licence. Available from: https://www.cancerdata.nhs.uk/

- National average

Quality of Life by Age group, % who reported any level of problem, Anxiety / depression (Reported problem) and Integrated Care Board

|	<50	50-59	60-69	70-79	80+
NHS BATH AND NORTH EAST SOMERSET, SWINDON AND WILTSHIRE INTEGRATED CARE BOARD	69.0%	62.5%	49.6%	46.6%	45.2%
NHS BEDFORDSHIRE, LUTON AND MILTON KEYNES INTEGRATED CARE BOARD	62.1%	55.0%	52.5%	53.2%	42.3%
NHS BIRMINGHAM AND SOLIHULL INTEGRATED CARE BOARD	78.7%	61.0%	62.1%	55.1%	48.2%
NHS BLACK COUNTRY INTEGRATED CARE BOARD	71.4%	72.5%	52.4%	44.2%	60.4%
NHS BRISTOL, NORTH SOMERSET AND SOUTH GLOUCESTERSHIRE INTEGRATED CARE BOARD	62.2%	59.2%	48.3%	45.3%	48.9%
NHS BUCKINGHAMSHIRE, OXFORDSHIRE AND BERKSHIRE WEST INTEGRATED CARE BOARD	61.2%	60.4%	49.9%	42.7%	46.3%
NHS CAMBRIDGESHIRE AND PETERBOROUGH INTEGRATED CARE BOARD	60.9%	61.3%	53.6%	48.4%	42.5%
NHS CHESHIRE AND MERSEYSIDE	69.1%	65.7%	54.0%	49.2%	47.0%

This dashboard has been created by Wilmington Healthcare and funded by Novartis Pharmaceuticals UK Limited, using data obtained from NHS England and publicly available sources.
UK|443803|May 2024 Privacy Policy: https://hsjmarketintelligence.co.uk/content/privacy-policy
Note: East of England South and East of England North cannot be merged.

Quality of life

Image

Breast Cancer Survival Analysis by Integrated Care Board

Click for more information

Wilmington Healthcare

| Home | Cancer Wait Times | Cancer Stage | Cancer Survival | Quality of Life | Patient Inequalities | System Inequalities | Methodology | Disclaimer |

Organisation Type
Integrated Care Board

Region
All

Organisation Name
NHS BATH AND NORTH EAST SOMERSE...

Time Since Diagnosis
3 years

Metric
Survival (%)

Age Group
All ages

Deprivation level: IMD Quintiles
% of Population in IMD Quintile 1

- National average

This work uses data that has been provided by patients and collected by the NHS as part of their care and support. The data is collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of NHS England (NHSE) and licensed under the Open Government Licence. Available from: https://www.cancerdata.nhs.uk/

NHS BATH AND NORTH EAST SOMERSET, SWINDON AND WILTSHIRE INTEGRATED CARE BOARD: Survival (%) at 3 years since diagnosis by age group

Age group	Survival (%)
All ages	93.4%
15 to 44	93.0%
45 to 54	97.3%
55 to 64	96.3%
65 to 74	95.3%
75 to 99	84.5%

Survival (%)

Survival (%) against % of population in IMD Quintile 1 by Integrated Care Board and 3 years since diagnosis

Survival (%)

% of Population in IMD Quintile 1 - increasing proportion of deprivation

This dashboard has been created by Wilmington Healthcare and funded by Novartis Pharmaceuticals UK Limited, using data obtained from NHS England and publicly available sources.
UK|443803|May 2024 Privacy Policy: https://hsjmarketintelligence.co.uk/content/privacy-policy

Cancer survival

Access the interactive Novartis Breast Cancer Health Inequalities Tool

Click here to view

Insights from the BC HI Tool can support the goal of reducing health inequalities across the NHS at a national and system level, aligning with the NHS Core20PLUS5 ambition. Drawing on deprivation data from the Office for National Statistics, the tool maps breast cancer outcomes in relation to deprivation at a national, Cancer Alliance and ICS level, providing a breakdown of outcomes data across deprivation quintiles.

Access the Novartis Health Inequalities Pledge

[Click here to view](#)

This dashboard has been created by Wilmington Healthcare and funded by Novartis Pharmaceuticals UK Limited, using data obtained from NHS England and publicly available sources.

Image

NOVARTIS

The Novartis Breast Cancer Health Inequalities Tool

User Guide

2024

Breast Cancer Health Inequalities Tool supporting user guide

PDF
[Download](#)

BC HI, Breast Cancer Health Inequalities; ICS, integrated care system; NHS, National Health Service.

UK | February 2025 | FA-11223209

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.